来凯医药(2105.HK)LAE002（Afuresertib）发《自然》杂志子刊，预示一个爆款BIC诞生

Core Viewpoint - The publication of the Phase 1b clinical study results for the AKT inhibitor Afuresertib (LAE002) in combination with Fulvestrant for HR+/HER2- advanced breast cancer demonstrates promising efficacy and safety, highlighting the potential for significant market opportunities in the treatment of this prevalent cancer subtype [1][3][18] Group 1: Clinical Study Insights - The Phase 1b study led by Academician Xu Binghe shows that Afuresertib combined with Fulvestrant exhibits potential efficacy and safety in patients with PIK3CA/AKT1/PTEN pathway alterations [1][5] - The ongoing Phase III study (AFFIRM-205) is expected to report data in the first half of 2026, with the Phase 1b results providing increased confidence for positive outcomes in the upcoming trial [1][15] - The Phase 1b study included a significant proportion of patients who had previously failed CDK4/6 inhibitor treatment, showcasing the potential of Afuresertib in this challenging patient population [7][8] Group 2: Market Potential - The global breast cancer drug market is projected to grow from approximately $38.2 billion in 2023 to $71.2 billion by 2032, with the HR+/HER2- subtype representing 60%-75% of breast cancer cases [3][16] - The market for second-line treatments for HR+/HER2- breast cancer, particularly those with PIK3CA/AKT1/PTEN alterations, is expected to be substantial, with estimates suggesting a market size of around 5 billion RMB [16] - Afuresertib's potential market share is estimated at 25%-30%, which could translate to sales peaks of approximately 1.5 billion RMB [16] Group 3: Competitive Landscape - Afuresertib's safety profile is highlighted as a competitive advantage over other AKT inhibitors like Capivasertib and Alpelisib, which have shown higher rates of adverse effects [11][12] - The Phase 1b study reported a 0% incidence of grade 3 hyperglycemia and a low rate of other adverse events, indicating a favorable safety profile that may enhance patient compliance [12][14] - The commercial success of Afuresertib is anticipated to be bolstered by its safety and efficacy, positioning it as a leading option in the AKT inhibitor market [11][14]